Biora Therapeutics (BIOR)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Biora Therapeutics, with a price target of $65.00. The company’s shares closed last Thursday at $2.80, close to its 52-week low of $1.95.
According to TipRanks.com, Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -10.0% and a 36.2% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Actinium Pharmaceuticals, and Checkpoint Therapeutics.
Biora Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $65.00.
Mizuho Securities analyst Mara Goldstein assigned a Buy rating to IN8bio today and set a price target of $12.00. The company’s shares closed last Thursday at $1.58, close to its 52-week low of $1.38.
According to TipRanks.com, Goldstein is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -3.0% and a 33.1% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for IN8bio with a $13.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BIOR: